Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07594093
PHASE1

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

Sponsor: Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-06-15

Completion Date

2027-02-22

Last Updated

2026-05-18

Healthy Volunteers

Yes

Interventions

DRUG

REGN20934

Administered per the protocol

DRUG

Placebo

Administered per the protocol